Concepedia

A. Santora

AS

Statistics

Publications

5

Citations

778

H-Index

5

Active since

2000

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, San Francisco

University of Maryland, Baltimore

A. Santora is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in osteoporosis, osteoporosis pharmacotherapy, and bone metabolism.

Publications per year

2000–2014

5

Publications

5

Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis

Thomas J. Schnitzer, Henry G. Bone, Gaetano Crepaldi et al. · Aging Clinical and Experimental Research · 2000 · 395 citations

, , +14

Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial

Douglas C. Bauer, Patrick Garnero, Marc C. Hochberg et al. · Journal of Bone and Mineral Research · 2006 · 188 citations · Full text

, , +16

Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy

Douglas C. Bauer, Ann V. Schwartz, Lisa Palermo et al. · JAMA Internal Medicine · 2014 · 130 citations

, , +16

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study

Toshitaka Nakamura, Masataka Shiraki, Masao Fukunaga et al. · Osteoporosis International · 2013 · 46 citations

, , +14

Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial

McClung, Bente Langdahl, Socrates E. Papapoulos et al. · ORBi (University of Liège) · 2014 · 19 citations

, , +13

1–5 of 5